Navigation Links
Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine),Clinical Data at the Annual NCDEU Meeting

PALO ALTO, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will present at the 47th Annual NCDEU Meeting the results of a Phase I clinical trial of Staccato loxapine (AZ-004), which is being developed for the treatment of acute agitation in patients with schizophrenia. The annual NCDEU meeting is co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology.

The poster presentation, "Novel inhalation technology delivers intravenous-like pharmacokinetics of loxapine in healthy volunteers" (Session 1-93), will be available for viewing at the meeting at the Mizner Center in Boca Raton, Florida on Tuesday, June 12, 2007 from 12:00 to 2:00 pm.

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has five product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.

CONTACT: Thomas B. King, Pesident & CEO of Alexza
'"/>




Page: 1 2

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at the American Headache Society Meeting
2. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
(Date:12/2/2009)...LAGE, Nev., Dec. 2 PDL B...ced that it has established the per share amount o...vidend as $1.67 per share. The dividend will be pa...any,s stock as of the December 1, 2009 record date...per share amount of the dividend at $1.67 per shar...
(Date:12/2/2009)...EJO, Calif., Dec. 2 Clar...and services resource for pathologists, oncologist... a Chief Financial Officer transition plan that ca...riguez to become its Senior Vice President and Chi...J. Land, age 64, the current Senior Vice President...
(Date:12/2/2009)...ST HANOVER, N.J., Dec. 2 Novartis ...eaking presentation on Tasigna® (nilotinib) 2...ia, demonstrate the strength of the company,s hema.... ,, The new data, at the 51st American Societ...n, highlight the company,s current therapies and i...
Breaking Medicine Technology:PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 3Clarient Announces CFO Transition Plan 2Clarient Announces CFO Transition Plan 3Clarient Announces CFO Transition Plan 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 1Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 2Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 3Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 1Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 2Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 3Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 4Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 5Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 6Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 7Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 8Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 1Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 2Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 3
...2/Insulin Significantly Lowered Blood Glucose with...ions,Phase 2 Trial Expected to Begin upon Ethics A... 2008, MELBOURNE, Australia, Aug. 8 ..., AIM: PSG, OTCQX: PPGNY) today,announced the succ...n,trial. The positive results of the trial demonst...
... Continued Investment in Clinical Development of T...uticals, Inc. (Nasdaq: TPPH ) announced today fin...7, 2007. The net loss for the second quarter of 2...pares to a net loss for the second quarter of 2006...the net loss for the second,quarter of 2007 and 20...
Other Medicine Technology:Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 3Tapestry Reports Second Quarter 2007 Results 2Tapestry Reports Second Quarter 2007 Results 3Tapestry Reports Second Quarter 2007 Results 4Tapestry Reports Second Quarter 2007 Results 5Tapestry Reports Second Quarter 2007 Results 6
(Date:12/2/2009)..., , ATLANTA, Dec. 2 In res...he U.S. military, FamilyLife, a non-profit ministr...will present its Weekend to Remember® marri...ry couples in Atlanta from Dec. 11 - 13 at the Gra...NE). Weekend to Remember is a marriage getaway ...
(Date:12/2/2009)..., , Ad in Today,s Washington Post H...swire-USNewswire/ -- If the Catholic bishops ha...tive measures we take for granted may be under thr...t to bear on the debate over healthcare reform has...shington Post warns of the likely impact if that ...
(Date:12/2/2009)..., , KANSAS CITY, Mo., Dec. 2 /PRN...mployers with a comprehensive, practical view on p...Congress. ,, (Logo: http://www.newscom.com/c...yers, there is good, bad, and ugly in the legislat...ttorneys in Lockton Benefit Group,s Compliance Se...
(Date:12/2/2009)...tudy finds myriad microbes in tobacco, but risk is...y News) -- New research provides evidence that th...ing bacteria that cause respiratory disease. , ... out, the authors of the new study aren,t sure wha...bacteria is nothing new: Microbes surround us ever...
(Date:12/2/2009)... Durham, NCDecember 2, 2009Ninety-six percent of l...dy on gender-based distrust indicated a strong gen...ver, this general distrust towards men did not pre...or romantic relationship. Furthermore, the union w...trusting," despite their prior assertions of distr...
Breaking Medicine News(10 mins):Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:Lockton Outlines Implications of Proposed Health Reform Plans 2Health News:Smokers Inhaling Germs With Each Cigarette 2
... cancer cells are able to spread to distant parts ...ells spread to the target site via the blood or th...re. It has now emerged that certain chemicals ...rs from the Cornell University's Weill Medical Col...
... speech can be processed much faster by the brain ...cochlear implant is carried out at an early age//,...ts. About 36 profoundly deaf children aged between...at seeing to what extent children with the implant...
...ducted to determine the effectiveness of 27 differ...evels; sunflower seeds and pistachio nuts have bee... of high levels of phytosterol (plant chemicals wh...tion. On analysis, sesame seeds and wheat ge...
...m passive bystanders to good Samaritans in situati...ers report//. Occasions when a crowd of people...l known. Psychologists call it the "bystander effe... can become knights in shining armour. An exp...
...om color blindness due to X-chromosome variations,...olors but have an increased sensitivity to differe... be differentiated by normal persons. The results ...olors are differentiated by the eyes by cone photo...
...University of Birmingham tested the 'Bambach Saddl..., and have concluded that it serves to relieve bac...ds, was found to keep the spine in its natural 'S'... given a task to perform. This was based on the po...
Other Medicine News:Health News:Initial Steps In Spread Of Cancer Identified 2Health News:Early Cochlear Implants Prove To Be Effective 2Health News:Colorblind Individuals have expanded color vision 2Health News:New Chair Invented To Relieve Backache 2
OneTouch® UltraSoft® Lancets
OneTouch® Fine Point™ Lancets
Microtainer Quikheel Lancet
HEMOCHRON Jr. Signature+ Microcoagulation System
Medicine Products: